

Chapter 40

Epidermal Necrolysis (Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis)

L. Valeyrie-Allanore & Jean-Claude Roujeau

REFERENCES

1. Stevens AM, Johnson FC: A new eruptive fever associated with stomatitis and ophthalmia: Report of two cases in children. *Am J Dis Child* **24**:526, 1922
2. Lyell A: Toxic epidermal necrolysis: An eruption resembling scalding of the skin. *Br J Dermatol* **68**:355, 1956 [PMID: 13374196]
3. Bastuji-Garin S et al: Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. *Arch Dermatol* **129**:92, 1993 [PMID: 8420497]
4. Lissia M et al: toxic epidermal necrolysis (Lyell's disease). *Burns* **36**:152, 2010 [PMID: 19766401]
5. Endorf FW et al: Toxic epidermal necrolysis clinical guidelines. *J Burn Care Res* **29**:706, 2008 [PMID: 18695603]
6. Ruiz-Maldonado R: Acute disseminated epidermal necrosis types 1, 2, and 3: Study of sixty cases. *J Am Acad Dermatol* **13**:623, 1985 [PMID: 4078051]
7. Lyell A: Requiem for toxic epidermal necrolysis. *Br J Dermatol* **122**:837, 1990 [PMID: 2369562]
8. Chan HL et al: The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: A population based study with particular reference to reactions caused by drugs among outpatients. *Arch Dermatol* **126**:43, 1990
9. Rzany B et al: Epidemiology of erythema exudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990–1992): Structure and results of a population-based registry. *J Clin Epidemiol* **49**:769, 1996 [PMID: 8691227]
10. Rzany B et al: Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with the acquired immunodeficiency syndrome in Germany. *Arch Dermatol* **129**:1059, 1993 [PMID: 8352614]
11. Roujeau JC et al: Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France (1981–1985). *Arch Dermatol* **126**:37, 1990 [PMID: 2134982]
12. Roujeau JC et al: Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. *N Engl J Med* **333**:1600, 1995 [PMID: 7477195]
13. Risser J et al: Mortality of bullous skin disorders from 1979 through 2002 in the United States. *Arch Dermatol* **145**:1005, 2009 [PMID: 19770439]
14. Bastuji-Garin S et al: SCORTEN: A severity-of-illness score for toxic epidermal necrolysis. *J Invest Dermatol* **115**:149, 2000 [PMID: 10951229]
15. Trent JT et al: Use of the SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States. *Arch Dermatol* **140**:890, 2004 [PMID: 15262712]
16. Brown KM et al: Toxic epidermal necrolysis: Does immunoglobulin make a difference? *J Burn Care Rehabil* **25**:81, 2004 [PMID: 14726744]
17. Guégan S et al: Performance of the SCORTEN during the first five days of hospitalisation to predict the prognosis of epidermal necrolysis. *J Invest Dermatol* **126**:272, 2006 [PMID: 17592442]
18. Cartotto R et al: SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center. *J Burn Care Res* **29**:141, 2008 [PMID: 18182912]
19. Lyell A: Toxic epidermal necrolysis (the scalded skin syndrome): A reappraisal. *Br J Dermatol* **100**:69, 1979 [PMID: 154918]
20. Roujeau JC, Stern RS: Severe adverse cutaneous reactions to drugs. *N Engl J Med* **331**:1272, 1994 [PMID: 7794310]
21. Stern RS, Chan HL: Usefulness of case report literature in determining drugs responsible for toxic epidermal necrolysis. *J Am Acad Dermatol* **21**:317, 1989 [PMID: 2671067]
22. Mockenhaupt M et al: Stevens-Johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. *J Invest Dermatol* **128**:35, 2008 [PMID: 17805350]

23. Auquier-Dunant A et al: Correlation between clinical patterns and causes of erythema multiforme major, Stevens Johnson and toxic epidermal necrolysis. *Arch Dermatol* **138**:1019, 2002 [PMID: 12164739]
24. Rzany B et al: Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: A case control study. *Lancet* **353**:2190, 1999 [PMID: 10392983]
25. Halevy S et al: Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. *J Am Acad Dermatol* **58**:25, 2008 [PMID: 17919772]
26. Fagot JP et al: Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. *AIDS* **15**:1843, 2001 [PMID: 11579247]
27. Mockenhaupt M et al: Risk of Stevens-Johnson and toxic epidermal necrolysis in new users of antiepileptics. *Neurology* **64**:1134, 2005 [PMID: 15824335]
28. Ketter TA et al: Dermatology precautions and slower titration yield low incidence of lamotrigine treatment–emergent rash. *J Clin Psychiatry* **66**:642, 2005 [PMID: 15889953]
29. Warnock JK, Morris DW: Adverse cutaneous reactions to mood stabilizers. *Am J Clin Dermatol* **4**:21, 2003 [PMID: 12477370]
30. Beran RG: Cross-reactive skin eruption with both carbamazepine and oxcarbamazepine. *Epilepsia* **34**:163, 1993 [PMID: 8422852]
31. Guillaume JC et al: The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome). *Arch Dermatol* **123**:1166, 1987 [PMID: 3632001]
32. Mockenhaupt M et al: The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: A multinational perspective. *J Rheumatol* **30**:2234, 2003 [PMID: 14528522]
33. Fournier S et al: Toxic epidermal necrolysis associated with Mycoplasma pneumoniae infection. *Eur J Clin Microbiol Infect Dis* **14**:558, 1995 [PMID: 7588837]
34. Adunsky A et al: Stevens-Johnson associated with Mycoplasma pneumoniae infection. *Cutis* **40**:123, 1987 [PMID: 3621995]
35. Stone N, Sheerin S, Burge S: Toxic epidermal necrolysis and graft versus host disease: A clinical spectrum but a diagnostic dilemma. *Clin Exp Dermatol* **24**:260, 1999 [PMID: 10457124]
36. Ting W et al: Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus and the spectrum of the acute syndrome of apoptotic pan-epidermolysis (ASAP): A case report, concept review and proposal for new classification of lupus erythematosus vesiculobullous skin lesions. *Lupus* **13**:941, 2004 [PMID: 15645750]
37. Fleisher AB Jr et al: Skin reactions to radiotherapy—A spectrum resembling erythema multiforme: Case report and review of the literature. *Cutis* **49**:35, 1992
38. Wohrl S et al: EMPACT syndrome. *J Dtsch Dermatol Ges* **3**:39, 2005 [PMID: 16353748]
39. Sassolas B et al: ALDEN, an algorithm for assessment of drug causality in Stevens–Johnson syndrome and toxic epidermal necrolysis: Comparison with case-control analysis. *Clin Pharmacol Ther* **88**(1):60–68, 2010 [Epub Apr 7, 2010]
40. Correia O et al: Cutaneous T-cell recruitment in toxic epidermal necrolysis: Further evidence of CD8+ lymphocyte involvement. *Arch Dermatol* **129**:466, 1993 [PMID: 8466217]
41. Paul C et al: Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. *Br J Dermatol* **134**:710, 1996 [PMID: 8733377]
42. Paquet P et al: Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis. *Arch Dermatol* **130**:605, 1994 [PMID: 8179342]
43. Le Cleach L et al: Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer inhibitory receptors. *Clin Exp Immunol* **119**:225, 2000
44. Nassif A et al: Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. *J Invest Dermatol* **118**:728, 2002 [PMID: 11918724]
45. Viard I et al: Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. *Science* **282**:490, 1998 [PMID: 9774279]
46. Abe R et al: Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas Ligand. *Am J Pathol* **162**:1515, 2003 [PMID: 12707034]
47. Berthou C et al: Acquisition of granzyme B and Fas ligand proteins by human keratinocytes contributes to epidermal cell defence. *J Immunol* **159**:5293, 1997 [PMID: 9548468]
48. Nassif A et al: Evaluation of the potential role of cytokines in toxic epidermal necrolysis. *J Invest Dermatol* **123**:850, 2004 [PMID: 15482470]
49. Stur K et al: Soluble FAS ligand: A discriminating feature between drug-induced skin eruptions and viral exanthemas. *J Invest Dermatol* **127**:802, 2007 [PMID: 17139262]

50. Chung WH et al: Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. *Nat Med* **14**:1343, 2008 [PMID: 19029983]
51. Abe R et al: Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome. *Ann Intern Med* **151**:514, 2009 [PMID: 19805776]
52. Kuechler PC et al: Cytotoxic mechanisms in different forms of T-cell-mediated drug allergies. *Allergy* **59**:613, 2004 [PMID: 15147446]
53. Azukizawa H et al: Prevention of toxic epidermal necrolysis by regulatory cells. *Eur J Immunol* **35**:1722, 2005 [PMID: 15909306]
54. Takahashi R et al: Defective regulatory T cells in patients with severe drug eruptions: Timing of the dysfunction is associated with the pathological phenotype and outcome. *J Immunol* **182**:8071, 2009 [PMID: 19494333]
55. Chung WH et al: Medical genetics: A marker for Stevens Johnson syndrome. *Nature* **428**:486, 2004 [PMID: 15057820]
56. Hung SI et al: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. *Proc Natl Acad Sci U S A* **102**:4134, 2005 [PMID: 15743917]
57. Locharenkul C et al: Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. *Epilepsia* **49**:2087, 2008 [PMID: 18637831]
58. Mehta TY et al: Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. *Indian J Dermatol Venereol Leprol* **75**:579, 2009 [PMID: 19915237]
59. Kaniwa N et al: HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. *Pharmacogenomics* **9**:1617, 2008 [PMID: 19018717]
60. Chung WH et al: Genetic predisposition of life-threatening antiepileptic-induced skin reactions. *Expert Opin Drug Saf* **9**:15, 2010 [PMID: 20001755]
61. Lonjou C et al: A marker for Stevens-Johnson syndrome: Ethnicity matters. *Pharmacogenomics J* **6**:265, 2006 [PMID: 16415921]
62. Lonjou C et al: A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. *Pharmacogenet Genomics* **18**:99, 2008 [PMID: 18192896]
63. Mockenhaupt M: Severe drug-induced skin reactions: Clinical pattern, diagnostics and therapy. *J Dtsch Dermatol Ges* **7**:142, 2009 [PMID: 19371237]
64. Shay E et al: Amniotic membrane transplantation as a new therapy for the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis. *Surv Ophthalmol* **54**:686, 2009 [PMID: 19699503]
65. Gueudry et al: Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. *Arch Dermatol* **145**:157, 2009 [PMID: 19221260]
66. Meneux E et al: Vulvovaginal involvement in toxic epidermal necrolysis: A retrospective study of 40 cases. *Obstet Gynecol* **91**:283, 1998 [PMID: 9469290]
67. Lebargy F et al: Pulmonary complications in toxic epidermal necrolysis: Prospective clinical study. *Intensive Care Med* **23**:1237, 1997 [PMID: 9470079]
68. McIvor RA et al: Acute and chronic respiratory complications of toxic epidermal necrolysis. *J Burn Care Rehabil* **17**:237, 1996 [PMID: 8736369]
69. Michel P et al: Ileal involvement in toxic epidermal necrolysis (Lyell syndrome). *Dig Dis Sci* **38**:1938, 1993 [PMID: 8404419]
70. Carter FM, Mitchell CK: Toxic epidermal necrolysis—An unusual cause of colonic perforation. Report of a case. *Dis Colon Rectum* **36**:773, 1993 [PMID: 8348869]
71. Blum L et al: Renal involvement in toxic epidermal necrolysis. *J Am Acad Dermatol* **34**:1088, 1996 [PMID: 8647982]
72. Krumlovsky FA et al: Renal disease associated with toxic epidermal necrolysis (Lyell's disease). *Am J Med* **57**:817, 1974 [PMID: 4440703]
73. Rzyany B et al: Histopathological and epidemiological characteristics of patients with erythema multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. *Br J Dermatol* **135**:6, 1996 [PMID: 8776350]
74. Quinn AM et al: Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. *Arch Dermatol* **141**:683, 2005 [PMID: 15967913]
75. Williams GP et al: Early pathological features of the cornea in toxic epidermal necrolysis. *Br J Ophthalmol* **91**:1129, 2007 [PMID: 17360733]
76. de Prost N et al: Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: Epidemiology, risk factors, and predictive value of skin cultures. *Medicine (Baltimore)* **89**:28, 2010 [PMID: 20075702]
77. Palmieri T et al: A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. *J Burn Care Rehabil* **23**:87, 2002 [PMID: 11882797]

78. Haber J et al: Late outcome in adult survivors of toxic epidermal necrolysis after treatment in burn center. *J Burn Care Rehabil* **26**:33, 2005 [PMID: 15640731]
79. Gaultier F et al: Severe and unrecognized dental abnormalities after drug-induced epidermal necrolysis. *Arch Dermatol* **145**:1332, 2009 [PMID: 19917972]
80. Bakirtas A et al: Bronchiolitis obliterans: A rare chronic pulmonary complication associated with Stevens-Johnson syndrome. *Pediatr Dermatol* **24**:E22, 2007 [PMID: 17845150]
81. Garcia-Doval I et al: Toxic epidermal necrolysis and Stevens-Johnson syndrome. Does early withdrawal of causative drugs decrease the risk of death? *Arch Dermatol* **136**:323, 2000 [PMID: 10724193]
82. Ellis MW: A case report and a proposed algorithm for the transfer of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis to a burn center. *Mil Med* **167**:701, 2002 [PMID: 12188246]
83. Lal S et al: Biobrane improves wound healing in burned children without increased risk of infection. *Shock* **14**:314, 2000 [PMID: 11028549]
84. Boorboor P et al: Toxic epidermal necrolysis: Use of Biobrane or skin coverage reduces pain, improves mobilisation and decreases infection in elderly patients. *Burns* **34**:487, 2008 [PMID: 17919820]
85. Dorafshar AH et al: Antishear therapy for toxic epidermal necrolysis: An alternative treatment approach. *Plast Reconstr Surg* **122**:154, 2008 [PMID: 18594400]
86. Kardaun SH, Jonkman MF: Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. *Acta Derm Venereol* **87**:144, 2007 [PMID: 17340021]
87. Schneck J et al: Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. *J Am Acad Dermatol* **58**:33, 2008 [PMID: 17919775]
88. Trent JT et al: Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN. *Arch Dermatol* **139**:39, 2003 [PMID: 12533162]
89. Prins C et al: Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins. *Arch Dermatol* **139**:26, 2003 [PMID: 12533160]
90. Stella M et al: Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): Experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis. *Burns* **33**:452, 2007 [PMID: 17475410]
91. Bachot N, Revuz J, Roujeau JC: Intravenous immunoglobulin treatment for Stevens-Johnson and toxic epidermal necrolysis. *Arch Dermatol* **139**:33, 2003 [PMID: 12533161]
92. Shortt R et al: Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. *J Burn Care Rehabil* **25**:246, 2004 [PMID: 15273465]
93. Arevalo JM et al: Treatment of toxic epidermal necrolysis with cyclosporine A. *J Trauma* **48**:473, 2000 [PMID: 10744287]
94. Valeyrie-Allanore L et al: Pilot study of ciclosporin treatment for Stevens–Johnson syndrome and toxic epidermal necrolysis. *Br J Dermatol* **163**(4):847-853, 2010
95. Bamichas G et al: Plasma exchange in patients with toxic epidermal necrolysis. *Ther Apher* **6**:225, 2002 [PMID: 12109948]
96. Chaidemenos GC et al: Plasmapheresis in toxic epidermal necrolysis. *Int J Dermatol* **36**:218, 1997 [PMID: 9159011]
97. Egan CA et al: Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. *J Am Acad Dermatol* **40**:458, 1999 [PMID: 10071318]
98. Lissia M, Figus A, Rubino C: Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: Preliminary report. *Br J Plast Surg* **58**:504, 2005 [PMID: 15897036]
99. Wolkenstein P et al: Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. *Lancet* **352**:1586, 1998 [PMID: 9843104]
100. Rosenthal P, Cotter J: The Boston Scleral Lens in the management of severe ocular surface disease. *Ophthalmol Clin North Am* **16**:89, 2003 [PMID: 12683251]
101. Tougeron-Brousseau B et al: Vision-related function after scleral lens fitting in ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. *Am J Ophthalmol* **148**:852, 2009 [PMID: 19837383]
102. Daya SM, Ilari FA: Living related conjunctival limbal allograft for the treatment of stem cell deficiency. *Ophthalmology* **108**:126, 2001 [PMID: 11150276]

103. Nishida K et al: Corneal reconstruction with tissue engineered cell sheets composed of autologous oral epithelium. *N Engl J Med* **351**:1187, 2004 [PMID: 15371576]
104. Wolkenstein P et al: Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. *Contact Dermatitis* **35**:234, 1996 [PMID: 8957644]
105. Kano Y et al: Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: Dependence on its timing and the type of drug eruption. *Allergy* **62**:1439, 2007 [PMID: 17983378]